Leaflet GLUADDA 50mg tablets

Indicated for: type 2 diabetes mellitus

Route of administration: oral

Substance: vildagliptin (DPP-4 inhibitor)

ATC: A10BH02 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Dipeptidyl peptidase 4 (DDP-4) inhibitors)

Vildagliptin is a medication used for the treatment of type 2 diabetes. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones. These hormones help regulate blood sugar by stimulating insulin secretion and reducing glucagon production, depending on blood glucose levels.

Vildagliptin is taken orally, usually once or twice daily, and can be used alone or in combination with other antidiabetic medications, such as metformin. It is effective in lowering blood sugar levels without typically causing episodes of hypoglycemia.

Side effects may include dizziness, headache, nausea, or, in rare cases, allergic reactions. It is important to use vildagliptin as directed by a healthcare provider, and patients should regularly monitor their blood sugar levels and maintain a healthy lifestyle to maximize the benefits of the treatment.

General data about GLUADDA 50mg

  • Substance: vildagliptin
  • Date of latest medicines list: 01-10-2025
  • Product code: W66805004
  • Concentration: 50mg
  • Pharmaceutical form: tablets
  • Quantity: 30
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: COMBINO PHARM (MALTA) LTD. - MALTA
  • Holder: MERCK ROMANIA SRL - ROMANIA
  • Number: 13276/2020/04
  • Shelf life: 3 years

Concentrations available for vildagliptin

  • 100mg
  • 50mg

Combinations with other substances